240 related articles for article (PubMed ID: 38058996)
21. Buprenorphine for Medication-Assisted Treatment of Opioid Use Disorder in Pregnancy: Relationship to Neonatal Opioid Withdrawal Syndrome.
Chavan NR; Ashford KB; Wiggins AT; Lofwall MR; Critchfield AS
AJP Rep; 2017 Oct; 7(4):e215-e222. PubMed ID: 29226017
[No Abstract] [Full Text] [Related]
22. Duration and Timing of In Utero Opioid Exposure and Incidence of Neonatal Withdrawal Syndrome.
Wang Y; Berger L; Durrance C; Kirby RS; Kuo D; Pac J; Ehrenthal DB
Obstet Gynecol; 2023 Sep; 142(3):603-611. PubMed ID: 37548391
[TBL] [Abstract][Full Text] [Related]
23. A Practical Approach to Neonatal Opiate Withdrawal Syndrome.
Devlin LA; Davis JM
Am J Perinatol; 2018 Mar; 35(4):324-330. PubMed ID: 29100261
[TBL] [Abstract][Full Text] [Related]
24. Reconceptualizing non-pharmacologic approaches to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS): A theoretical and evidence-based approach.
Velez ML; Jordan CJ; Jansson LM
Neurotoxicol Teratol; 2021; 88():107020. PubMed ID: 34419619
[TBL] [Abstract][Full Text] [Related]
25. Understanding barriers to timely identification of infants at risk of neonatal opiate withdrawal syndrome.
Howell MP; Smith AM; Lindsay EB; Drury SS
J Matern Fetal Neonatal Med; 2021 Apr; 34(7):1161-1166. PubMed ID: 31195865
[TBL] [Abstract][Full Text] [Related]
26. Enduring consequences of perinatal fentanyl exposure in mice.
Alipio JB; Brockett AT; Fox ME; Tennyson SS; deBettencourt CA; El-Metwally D; Francis NA; Kanold PO; Lobo MK; Roesch MR; Keller A
Addict Biol; 2021 Mar; 26(2):e12895. PubMed ID: 32187805
[TBL] [Abstract][Full Text] [Related]
27. Risk Factors Associated with the Occurrence of Neonatal Opioid Withdrawal Syndrome: A Review.
Kelty E; Preen DB
CNS Drugs; 2019 Nov; 33(11):1113-1120. PubMed ID: 31686408
[TBL] [Abstract][Full Text] [Related]
28. Trajectories of Prescription Opioid Utilization During Pregnancy Among Prepregnancy Chronic Users and Risk of Neonatal Opioid Withdrawal Syndrome.
Straub L; Huybrechts KF; Hernández-Díaz S; Zhu Y; Vine S; Desai RJ; Gray KJ; Bateman BT
Am J Epidemiol; 2022 Jan; 191(1):208-219. PubMed ID: 34643225
[TBL] [Abstract][Full Text] [Related]
29. Opioid withdrawal behavior in spiny mice: A novel preclinical model of neonatal opioid withdrawal syndrome (NOWS).
Stevens S; Mohan S
Heliyon; 2021 Apr; 7(4):e06694. PubMed ID: 33898824
[TBL] [Abstract][Full Text] [Related]
30. Opioids and the developing brain: time to rethink perinatal care for infants of opioid-dependent mothers.
Boardman JP; Mactier H; Devlin LA
Arch Dis Child Fetal Neonatal Ed; 2022 Jan; 107(1):98-104. PubMed ID: 33597225
[TBL] [Abstract][Full Text] [Related]
31. Gestational buprenorphine exposure: Effects on pregnancy, development, neonatal opioid withdrawal syndrome, and behavior in a translational rodent model.
Wallin CM; Bowen SE; Roberge CL; Richardson LM; Brummelte S
Drug Alcohol Depend; 2019 Dec; 205():107625. PubMed ID: 31706250
[TBL] [Abstract][Full Text] [Related]
32. Impact of In-utero Exposure to Selective Serotonin Reuptake Inhibitors and Opioids on Neonatal Opioid Withdrawal Syndrome.
Bhatt-Mehta V; Richards J; Sturza J; Schumacher RE
J Addict Med; 2019; 13(3):227-234. PubMed ID: 30489344
[TBL] [Abstract][Full Text] [Related]
33. Decreased myelin-related gene expression in the nucleus accumbens during spontaneous neonatal opioid withdrawal in the absence of long-term behavioral effects in adult outbred CFW mice.
Borrelli KN; Wingfield KK; Yao EJ; Zamorano CA; Sena KD; Beierle JA; Roos MA; Zhang H; Wachman EM; Bryant CD
bioRxiv; 2023 Aug; ():. PubMed ID: 37609129
[TBL] [Abstract][Full Text] [Related]
34. The Time is NOW: Filling the Gaps in Treatment of Opioid-Exposed Infants: A Prospective, Pragmatic, Randomized Control Drug Trial.
Czynski AJ; Laptook AR
R I Med J (2013); 2021 Apr; 104(3):17-21. PubMed ID: 33789403
[TBL] [Abstract][Full Text] [Related]
35. A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based pharmacokinetic modeling to improve the treatment of neonatal opioid withdrawal syndrome.
van Hoogdalem MW; Wexelblatt SL; Akinbi HT; Vinks AA; Mizuno T
Pharmacol Ther; 2022 Jun; 234():108045. PubMed ID: 34813863
[TBL] [Abstract][Full Text] [Related]
36. Neurobehavioral effects of neonatal opioid exposure in mice: Influence of the OPRM1 SNP.
Robinson SA; Jones AD; Brynildsen JK; Ehrlich ME; Blendy JA
Addict Biol; 2020 Sep; 25(5):e12806. PubMed ID: 31267641
[TBL] [Abstract][Full Text] [Related]
37. Automated quantification of opioid withdrawal in neonatal rat pups using Ethovision® XT software.
Kulbeth HJ; Fukuda S; Brents LK
Neurotoxicol Teratol; 2021; 84():106959. PubMed ID: 33529734
[TBL] [Abstract][Full Text] [Related]
38. Fetal gastric area ratio to predict severe neonatal opioid withdrawal syndrome.
Townsel C; Stone J; Debolt C; Hussain N; Campbell WA
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):7957-7961. PubMed ID: 34151686
[TBL] [Abstract][Full Text] [Related]
39. The Influence of Mediators on the Relationship Between Antenatal Opioid Agonist Exposure and the Severity of Neonatal Opioid Withdrawal Syndrome.
Devlin LA; Hu Z; Ounpraseuth S; Simon AE; Annett RD; Das A; Fuller JF; Higgins RD; Merhar SL; Smith PB; Crawford MM; Cottrell LE; Czynski AJ; Newman S; Paul DA; Sánchez PJ; Semmens EO; Smith MC; Whalen BL; Snowden JN; Young LW;
Matern Child Health J; 2023 Jun; 27(6):1030-1042. PubMed ID: 36905529
[TBL] [Abstract][Full Text] [Related]
40. Placental microRNA methylome signatures may serve as biomarkers and therapeutic targets for prenatally opioid-exposed infants with neonatal opioid withdrawal syndrome.
Radhakrishna U; Nath SK; Uppala LV; Veerappa A; Forray A; Muvvala SB; Metpally RP; Crist RC; Berrettini WH; Mausi LM; Vishweswaraiah S; Bahado-Singh RO
Front Genet; 2023; 14():1215472. PubMed ID: 37434949
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
